These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1106845)

  • 21. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.
    Cavalli F; Sonntag RW; Jungi F; Senn HJ; Brunner KW
    Cancer Treat Rep; 1978 Mar; 62(3):473-5. PubMed ID: 348319
    [No Abstract]   [Full Text] [Related]  

  • 22. [Phase I clinical study of NK 171 (etoposide)].
    Kimura K; Yamada K; Niitani H
    Gan To Kagaku Ryoho; 1985 Apr; 12(4):851-6. PubMed ID: 2985006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Phase I study of an oral administration of VP 16-213].
    Ogawa M; Ota K; Oyama A; Fukuoka M; Takada M; Yoshida S; Sanpi K; Kimura I; Ohnoshi T; Kuraishi Y
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2403-7. PubMed ID: 6639102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].
    Konishi I; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
    Gan To Kagaku Ryoho; 1985 Jul; 12(7):1482-6. PubMed ID: 4015122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II clinical trial of VP-16-213 in ovarian cancer.
    Maskens AP; Armand JP; Lacave AJ; De Jager RL; Hansen HH; Wolff JP
    Cancer Treat Rep; 1981; 65(3-4):329-30. PubMed ID: 7016320
    [No Abstract]   [Full Text] [Related]  

  • 26. VP-16-213. A phase II trial using a weekly schedule.
    Karp G; Antman K; Canellos G
    Cancer Clin Trials; 1981; 4(4):465-7. PubMed ID: 7318129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.
    Cohen MH; Broder LE; Fossieck BE; Ihde DC; Minna JD
    Cancer Treat Rep; 1977; 61(3):489-90. PubMed ID: 194694
    [No Abstract]   [Full Text] [Related]  

  • 28. Oral etoposide in gestational trophoblastic disease.
    Wong LC; Choo YC; Ma HK
    Cancer Treat Rep; 1984 May; 68(5):775-7. PubMed ID: 6327035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A phase II study of intravenous VP-16-213 in small cell and non-small cell carcinoma of the lung].
    Konno K; Nagahama F; Nakai Y; Nakabayashi T; Hiraga Y; Takebe K; Tamura M; Oizumi K; Sato M; Ito T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):931-7. PubMed ID: 3008671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A phase II study of oral VP-16 in primary lung cancer].
    Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
    Robert F; Chen S; Miller AA; Lee BC; Molthrop DC; Wheeler RH
    Cancer Chemother Pharmacol; 1996; 38(5):459-65. PubMed ID: 8765440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study.
    Panduro J; Hansen M; Hansen HH
    Cancer Treat Rep; 1981; 65(7-8):703-4. PubMed ID: 7248987
    [No Abstract]   [Full Text] [Related]  

  • 33. Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer.
    Grunberg SM; Felman IE; Gala KV; Johnson KB; Owens JC
    Am J Clin Oncol; 1985 Oct; 8(5):393-5. PubMed ID: 4061373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Teniposide in epithelial ovarian carcinoma: a phase II trial of the Gynecologic Oncology Group.
    Muss H; Bundy BN; DiSaia PJ; Twiggs LB
    Cancer Treat Rep; 1986 Oct; 70(10):1231-2. PubMed ID: 3530450
    [No Abstract]   [Full Text] [Related]  

  • 35. VP-16-213 in the treatment of stage III and IV diffuse lymphocytic lymphoma of the large cell (histiocytic) variety: an interim report.
    Jacobs P; King HS; Cassidy F; Dent DM; Harrison T
    Cancer Treat Rep; 1981; 65(11-12):987-93. PubMed ID: 7028260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group.
    Anderson G; Payne H
    Semin Oncol; 1985 Mar; 12(1 Suppl 2):21-2. PubMed ID: 3883504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).
    Creaven PJ; Newman SJ; Selawry OS; Cohen MH; Primack A
    Cancer Chemother Rep; 1974; 58(6):901-7. PubMed ID: 4615787
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer.
    Crivellari D; Veronesi A; Magri MD; Tirelli U; Comoretto R; Barzan L; Caruso G; Carbone A; Grigoletto E
    Tumori; 1985 Oct; 71(5):499-500. PubMed ID: 4060251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Etoposide: VP-16].
    Dicato M
    Bull Soc Sci Med Grand Duche Luxemb; 1982; 119(2):15-8. PubMed ID: 7160031
    [No Abstract]   [Full Text] [Related]  

  • 40. [Randomized phase II study with VP-16-213 (etoposide) in the treatment of advanced breast cancer].
    Cavalli F; Jungi WF; Brunner KW
    Onkologie; 1981 Apr; 4(2):80-3. PubMed ID: 7022286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.